BR112012001047A2 - composições compreendendo um inibidor de colinesterase para tratar distúrbios cognitivos - Google Patents
composições compreendendo um inibidor de colinesterase para tratar distúrbios cognitivosInfo
- Publication number
- BR112012001047A2 BR112012001047A2 BR112012001047A BR112012001047A BR112012001047A2 BR 112012001047 A2 BR112012001047 A2 BR 112012001047A2 BR 112012001047 A BR112012001047 A BR 112012001047A BR 112012001047 A BR112012001047 A BR 112012001047A BR 112012001047 A2 BR112012001047 A2 BR 112012001047A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- cognitive disorders
- cholinesterase inhibitor
- treating cognitive
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22642509P | 2009-07-17 | 2009-07-17 | |
| PCT/US2010/042308 WO2011009061A1 (en) | 2009-07-17 | 2010-07-16 | Compositions comprising a cholinesterase inhibitor for treating cognitive disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012001047A2 true BR112012001047A2 (pt) | 2019-09-24 |
Family
ID=42990151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012001047A BR112012001047A2 (pt) | 2009-07-17 | 2010-07-16 | composições compreendendo um inibidor de colinesterase para tratar distúrbios cognitivos |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20110015179A1 (pt) |
| EP (1) | EP2453890B1 (pt) |
| JP (1) | JP2012533566A (pt) |
| KR (1) | KR101757003B1 (pt) |
| CN (1) | CN102497861A (pt) |
| AU (1) | AU2010273977A1 (pt) |
| BR (1) | BR112012001047A2 (pt) |
| CA (1) | CA2768356A1 (pt) |
| DK (1) | DK2453890T3 (pt) |
| ES (1) | ES2809298T3 (pt) |
| IN (1) | IN2012DN01209A (pt) |
| PT (1) | PT2453890T (pt) |
| RU (2) | RU2016151986A (pt) |
| WO (1) | WO2011009061A1 (pt) |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5A (en) * | 1836-08-10 | Thomas blancharjq | ||
| US4166452A (en) * | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US5409948A (en) * | 1992-11-23 | 1995-04-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method for treating cognitive disorders with phenserine |
| US20050222123A1 (en) | 2004-01-27 | 2005-10-06 | North Shore-Long Island Jewish Research Institute | Cholinesterase inhibitors for treating inflammation |
| US20070212253A1 (en) * | 2004-12-21 | 2007-09-13 | Elrod Scott A | Descenting systems and methods |
| WO2006081276A1 (en) * | 2005-01-26 | 2006-08-03 | Allergan, Inc. | 3-heteroaryl-3-hydroxy-2-amino-propyl amines and related compounds having analgesic and/or immuno stimulant activity |
| WO2007012154A1 (en) * | 2005-07-27 | 2007-02-01 | Carlos Henrique Horta Lima | Pharmaceutical preparation containing an acetylcholinesterase ihibitor and an antidepressant with 5-ht and alpha-2-adrenoceptor blocking properties. |
| CA2620333A1 (en) * | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| ES2383384T3 (es) * | 2007-03-06 | 2012-06-20 | Allergan, Inc. | Un derivado de amidas de ácidos 3-heteroaril-3-hidroxi-2-aminopropiónicos específico para su uso en el tratamiento de ciertos trastornos cognitivos |
| US20100190792A1 (en) * | 2007-03-06 | 2010-07-29 | Allergan, Inc | Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds |
| WO2008109286A1 (en) * | 2007-03-06 | 2008-09-12 | Allergan, Inc. | Methods for treating cognitive disorders using 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds |
| WO2008109285A1 (en) | 2007-03-06 | 2008-09-12 | Allergan, Inc. | Methods for treating cognitive disorders |
| BRPI0813832A2 (pt) * | 2007-07-17 | 2015-01-06 | Allergan Inc | Métodos para tratamento da ansiedade |
-
2010
- 2010-07-16 BR BR112012001047A patent/BR112012001047A2/pt not_active IP Right Cessation
- 2010-07-16 JP JP2012520814A patent/JP2012533566A/ja active Pending
- 2010-07-16 CN CN201080041187XA patent/CN102497861A/zh active Pending
- 2010-07-16 RU RU2016151986A patent/RU2016151986A/ru not_active Application Discontinuation
- 2010-07-16 US US12/838,019 patent/US20110015179A1/en not_active Abandoned
- 2010-07-16 AU AU2010273977A patent/AU2010273977A1/en not_active Abandoned
- 2010-07-16 DK DK10735143.9T patent/DK2453890T3/da active
- 2010-07-16 EP EP10735143.9A patent/EP2453890B1/en active Active
- 2010-07-16 ES ES10735143T patent/ES2809298T3/es active Active
- 2010-07-16 RU RU2012103401A patent/RU2607946C2/ru not_active Application Discontinuation
- 2010-07-16 IN IN1209DEN2012 patent/IN2012DN01209A/en unknown
- 2010-07-16 PT PT107351439T patent/PT2453890T/pt unknown
- 2010-07-16 WO PCT/US2010/042308 patent/WO2011009061A1/en active Application Filing
- 2010-07-16 KR KR1020127003979A patent/KR101757003B1/ko active IP Right Grant
- 2010-07-16 CA CA2768356A patent/CA2768356A1/en not_active Abandoned
-
2012
- 2012-10-11 US US13/649,404 patent/US9492543B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DK2453890T3 (da) | 2020-08-17 |
| RU2607946C2 (ru) | 2017-01-11 |
| IN2012DN01209A (pt) | 2015-04-10 |
| WO2011009061A1 (en) | 2011-01-20 |
| EP2453890A1 (en) | 2012-05-23 |
| KR20120090029A (ko) | 2012-08-16 |
| AU2010273977A1 (en) | 2012-02-02 |
| KR101757003B1 (ko) | 2017-07-11 |
| US20110015179A1 (en) | 2011-01-20 |
| EP2453890B1 (en) | 2020-05-27 |
| ES2809298T3 (es) | 2021-03-03 |
| US20130040938A1 (en) | 2013-02-14 |
| RU2016151986A (ru) | 2018-12-19 |
| CA2768356A1 (en) | 2011-01-20 |
| US9492543B2 (en) | 2016-11-15 |
| JP2012533566A (ja) | 2012-12-27 |
| CN102497861A (zh) | 2012-06-13 |
| PT2453890T (pt) | 2020-08-25 |
| RU2012103401A (ru) | 2013-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0918527A2 (pt) | compostos para o tratamento de disturbios do cns | |
| DK2421825T3 (da) | Azetidinyldiamider som monoacylglycerollipase-inhibitorer | |
| BRPI0915205A2 (pt) | compostos e composições úteis para o tratamento de malária | |
| BR112012002780A2 (pt) | métodos, compostos, e composições para a aplicação de ácido 1,3-propanodisulfônico | |
| BRPI0906391A2 (pt) | Máscara higiênica para proteção de outros | |
| BRPI1013561A8 (pt) | processo para a preparação de alogliptina | |
| BRPI1012574A2 (pt) | distribuição de tensão de estria aperfeiçoada | |
| BR112012011730A2 (pt) | tratamentos para distúrbios gastrointestinais | |
| BRPI1015274A2 (pt) | instalação para o tratamento de superfície de peças | |
| BR112012004080A2 (pt) | composições farmacêuticas para tratar ibd | |
| BRPI1008664A2 (pt) | comprimidos para a terapia de combinação | |
| BRPI0920009A2 (pt) | composições concentradas para tratamento de superfícies rígidas | |
| BRPI1007600A2 (pt) | composições e métodos para tratamento de doenças cardiovasculares | |
| BRPI1013830A2 (pt) | Processo para a iodação de compostos aromáticos | |
| IL223078A (en) | Preparation for the Durability Disorders of Methotrexate Containing 10-Propargil-10-Dazaminoprotein | |
| BR112012006437A2 (pt) | composições e métodos para tratamento do diabetes e outros distúrbios | |
| BR112013012835A2 (pt) | processo de fcc para desmetanizador absorvente | |
| BR112012015929A2 (pt) | equipamento para instalação de um implante | |
| BRPI1007529A2 (pt) | métodos para regeneração de tecido pancreático | |
| BRPI1010571A2 (pt) | processo para a preparação de um composto útil como um inibidor de tafla. | |
| BR112012001731A2 (pt) | Processo para a preparação de 1-benzil-3-hidroximetil-1h-indazol | |
| BRPI0920728A2 (pt) | Composição estabilizada para tratamento de psoríase | |
| BRPI0921210A2 (pt) | processos para a preparação de compostos de arilaminas | |
| BRPI1010841A2 (pt) | método para a fabricação de fluoroalquilnitrilas | |
| BR112012001463A2 (pt) | métodos e composições para tratar e prevenir doença associada à integrina alfavbeta5 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |